Taiko Pharmaceutical Co., Ltd. (JP:4574)
:4574
Want to see JP:4574 full AI Analyst Report?
4574 Stock Chart & Stats
¥305.00
-¥2.00(-0.62%)
At close: 4:00 PM EST
¥305.00
-¥2.00(-0.62%)
Day’s Range― - ―
52-Week Range¥239.00 - ¥444.00
Previous CloseN/A
Volume146.60K
Average Volume (3M)93.84K
Market Cap
¥12.62B
Enterprise Value¥10.01B
Total Cash (Recent Filing)¥4.14B
Total Debt (Recent Filing)¥1.32B
Price to Earnings (P/E)23.5
Beta0.71
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.23
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.9
Revenue Forecast (FY)¥6.75B
Bulls Say, Bears Say
Bulls Say
Improved LeverageMarked reduction in debt materially lowers financial risk and increases strategic optionality. With debt under ¥1B and equity ~¥8.52B (2025), the company can better fund R&D, manufacturing or licensing without urgent external financing, improving resilience across cycles.
Return To Profitability & Cash FlowSustained net income and positive operating and free cash flow in 2024–2025 indicate the business can convert operations into real cash. That improves capacity to reinvest, pay obligations, and pursue partnerships without relying on volatile capital markets.
Stabilizing Revenue GrowthA return to modest, consistent top-line growth after prior declines signals product-market traction and demand stability. Reestablished revenue momentum supports margin leverage, planning for manufacturing capacity, and predictable cash generation over months.
Bears Say
Multi-year Earnings VolatilityLarge swings from strong profits to heavy losses in recent years undermine confidence in earnings durability. This volatility complicates long-range planning, partnership negotiations, and investment decisions, raising execution risk for sustained recovery.
Unproven Cash Conversion ConsistencyAlthough FCF turned positive, weaker cash conversion relative to accounting profits suggests earnings may rely on timing or noncash items. If working-capital swings reoccur, cash flow and debt servicing could be stressed despite reported profitability.
Declining Asset BaseA shrinking asset base over several years may reflect reduced scale or underinvestment in capacity and R&D. Persisting shrinkage can limit manufacturing scale, negotiating leverage with partners, and future growth opportunities unless reversed.
Taiko Pharmaceutical Co., Ltd. News
4574 FAQ
What was Taiko Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Taiko Pharmaceutical Co., Ltd. lowest stock price was ¥239.00 and its highest was ¥444.00 in the past 12 months.
What is Taiko Pharmaceutical Co., Ltd.’s market cap?
Taiko Pharmaceutical Co., Ltd.’s market cap is ¥12.62B.
When is Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 62 days.
How were Taiko Pharmaceutical Co., Ltd.’s earnings last quarter?
Taiko Pharmaceutical Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥1.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.89.
Is Taiko Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Taiko Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Taiko Pharmaceutical Co., Ltd. pay dividends?
Taiko Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥13 which represents an annual dividend yield of N/A. See more information on Taiko Pharmaceutical Co., Ltd. dividends here
What is Taiko Pharmaceutical Co., Ltd.’s EPS estimate?
Taiko Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taiko Pharmaceutical Co., Ltd. have?
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding.
What happened to Taiko Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Taiko Pharmaceutical Co., Ltd. reported an EPS of -¥1.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Taiko Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Nippon Chemiphar Co., Ltd.
―